The PATAGONIA Study is evaluating whether an investigational drug (a drug not approved for clinical use) is safe and effective at treating moderate to severe tremor caused by Parkinson’s disease in adults whose tremor continues despite treatment with standard Parkinson’s medications.
The trial involves up to 20 visits, including 9 office visits and 11 phone visits, over the course of up to 23 weeks. Potential participants who qualify and meet all eligibility criteria are randomly assigned to 1 of 2 groups. Participants receive either the investigational drug or a placebo (a substance that looks like the investigational drug but contains no medicine), both taken orally (by mouth). Approximately 160 participants will be enrolled, and they may be reimbursed for travel and expenses.
We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
For more detailed information on the cookies we use, please check our Privacy Policy.
By continuing to access this website, you are giving us consent to collect cookies.
